Our Research and New Product Development

Our science team, supported by university research and selected medical practitioners, work tirelessly and with dedication in performing ongoing research and new product development with the vision and mission of relieving human and animal suffering resulting from degenerative medical conditions.

We have assembled a highly skilled and qualified team of scientists and clinical experts to undertake our Research and New Product Development, through which we manage both new and pioneering research, along with the further exploration of new and improved applications of our existing Core Technologies.


The Company, has undertaken the development of in-vitro-generated 3D organ tissue buds utilizing the peripheral blood derived pluripotent stem cells recovered utilizing its PBD-PSC Technology both for supply of various organ tissues for laboratory research and testing and as a promising approach toward regenerating functional and vascularized organs including kidney, pancreas, intestine, heart, lung, and brain.


Tithon, through the Technology Transfer Agreement entered into with Paspa Pharmaceutical Pty. Ltd., obtained and possesses all future rights titles and interests in and to a proprietary novel cross-linking method of sodium alginate, which has been demonstrated to produce a stronger bond, useful in a number of commercial applications (the “Alginate Technology”).

 The Alginate Technology is based on discoveries by Paspa and Dr. Paspaliaris who discovered a method for cross linking sodium alginate resulting in a superior bond, to that available using the current method of utilizing calcium for cross-linking alginate. Testing has shown that not only was a superior bond produced, but the resulting material possessed antimicrobials qualities, resulting in both non-medical applications and, due to its unique properties, medical applications. These characteristics suggest that this method could be commercialized for: (i) non-medical uses in the food industry, the textile and paper industries, the welding and molding industries; and (ii) medical uses in producing wound care dressings, oral delivery of proteins, construction of scaffolds in tissue engineering, and utilizing with the PBD-PSC Technology, in 3D Bioprinting and encapsulation.


The Company’s scientists have been able to differentiate peripheral blood derived pluripotent stem cells into primordial germ cells, embryoid bodies and then to oocyte-like cells. These oocyte-like cells express the markers resembling oocytes. The Company’s scientists are now actively observing whether these generated oocytes from peripheral blood derived pluripotent stem cells can develop spontaneously into blastocyst-like embryos via parthenogenetic activation or via sperm fertilization.

Besides using these findings for further studies aimed at perfecting the autologous treatment of ovarian infertility, it will also lead to a better understanding of overall ovarian physiology and the discovery of better drug candidates for treatment of ovarian disease or dysfunction. More importantly, this could lead to the autologous synthesis in culture of a woman’s oocytes for fertilization via standard IVF procedures.


The Company’s scientists have recently conducted initial investigation into the physiological role of Parathyroid Hormone (PTHrP) in the activation of the stem cells that are utilized in its proprietary method employed in both the SCOREsm and SCUPEsm treatments. Scientific studies conducted by Dr. Paspaliaris, and other scientific groups since 1989, have shown that PTHrP is expressed locally in areas of trauma and injury as well as with mechanotransduction (stretch). Since this distinct population of pluripotent stem cells highly express parathyroid hormone type 1 receptors, to which PTHrP bind, and are circulating in the peripheral blood, it was postulated by Dr. Paspaliaris that PTHrP acts as a chemoattractant to these cells upon injury, similar to what has been shown for Stromal Cell-Derived Factor -1 (SDF-1). Initial in vitro work conducted by Dr. Paspaliaris suggests this is the case and PTHrP acts as a chemoattractant to these PTHR-PSC cells upon injury similar to SDF-1, which may also explain the anabolic and regenerative effects attributed to PTH and PTHrP and their peptide analogues. Eli Lilly’s drug Forteo is a peptide analogue of PTH and is used for anabolic therapy of bone in patients suffering from osteoporosis


Tithon Biomaterials is currently conducting further research and development in the use of 3D Printers as a regenerative medicine tool used to make three dimensional tissues. Currently this technology is capable of producing heterogeneous biological support tissues for use in reconstructive surgery to treat patients with degenerative diseases. With success in producing bone and many different soft tissues, this technology can be used as an initial step towards producing many different tissue types for reconstructive surgery or for research.


A proprietary method to discover new peptide based drugs via electromagnetic energy computations for use in finding peptide candidates that can either inhibit or activate Protein Receptors.



Enquire about our New Research and Product Development

3 + 10 =

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.